The disclosure herein relates generally to immunotherapy, and more specifically to the use of immunotherapy to treat tumors and pathogen-infected tissues. Immunotherapy involves first priming the patient with allogeneic cells designed to be rejected by a Th1-mediated mechanism and then inducing necrosis or apoptosis in situ in the tumor or pathogen infected lesion. Necrosis or apoptosis is a method applied to at least a portion of a tumor or pathogen infected tissue, such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave heat ablation, radiofrequency energy or its It can be induced by combination. One or more doses of allogeneic cells (eg, Th1 cells) are then delivered to a location within or proximate to the tumor or pathogen-infected tissue of the primed patient. The present invention provides immunotherapeutic strategies for generating novel systemic (adaptive) immunity against tumors or pathogens.
展开▼
